Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases
Hierarchy View
Subtype Terms (47)
Acneiform Eruptions
3 drugs (2 approved, 1 experimental)
Angiolymphoid Hyperplasia with Eosinophilia
Breast Diseases
72 drugs (60 approved, 12 experimental)
Dermatitis
38 drugs (24 approved, 14 experimental)
Dermatomyositis
65 drugs (39 approved, 26 experimental)
Erythema
37 drugs (25 approved, 12 experimental)
Exanthema
24 drugs (21 approved, 3 experimental)
Facial Dermatoses
1 approved drug
Foot Diseases
4 approved drugs
Hair Diseases
2 drugs (1 approved, 1 experimental)
Hand Dermatoses
8 drugs (6 approved, 2 experimental)
Keratoacanthoma
3 approved drugs
Keratosis
16 drugs (8 approved, 8 experimental)
Lupus Erythematosus, Cutaneous
35 drugs (13 approved, 22 experimental)
Nail Diseases
7 drugs (4 approved, 3 experimental)
Necrolytic Migratory Erythema
1 approved drug
Nephrogenic Fibrosing Dermopathy
5 drugs (4 approved, 1 experimental)
Panniculitis
2 drugs (1 approved, 1 experimental)
Photosensitivity Disorders
7 drugs (5 approved, 2 experimental)
Pigmentation Disorders
8 drugs (7 approved, 1 experimental)
Prurigo
15 drugs (10 approved, 5 experimental)
Pruritus
130 drugs (77 approved, 53 experimental)
Pyoderma
5 drugs (1 approved, 4 experimental)
Rosacea
62 drugs (38 approved, 24 experimental)
Scalp Dermatoses
1 approved drug
Scleredema Adultorum
1 experimental drug
Scleroderma, Localized
9 drugs (7 approved, 2 experimental)
Scleroderma, Systemic
152 drugs (86 approved, 66 experimental)
Skin Abnormalities
12 drugs (4 approved, 8 experimental)
Skin Diseases, Eczematous
9 drugs (8 approved, 1 experimental)
Skin Diseases, Genetic
8 drugs (5 approved, 3 experimental)
Skin Diseases, Infectious
43 drugs (36 approved, 7 experimental)
Skin Diseases, Papulosquamous
5 drugs (4 approved, 1 experimental)
Skin Diseases, Vesiculobullous
2 drugs (1 approved, 1 experimental)
Skin Neoplasms
139 drugs (80 approved, 59 experimental)
Skin Ulcer
7 drugs (4 approved, 3 experimental)
Sweat Gland Diseases
4 drugs (3 approved, 1 experimental)
Xanthogranuloma, Juvenile
3 drugs (1 approved, 2 experimental)
Approved Indicated Drugs (27)
Phase 4 Indicated Drugs (14)
Phase 3 Indicated Drugs (17)
Phase 2 Indicated Drugs (26)
Phase 1 Indicated Drugs (5)
Other Experimental Indicated Drugs (19)
Organization Involved with Phase 4 Indications (43)
Jining City Dermatology Hospital Prevention and Treatment
Laiwu City Dermatology Hospital Prevention and Treatment
Rizhao City Dermatology Hospital Prevention and Treatment
Shandong Jining No. 1 People's Hospital
Shandong Province Qianfoshan Hospital
Shandong Provincial Institute of Dermatology and Venereology
Organization Involved with Phase 3 Indications (22)
Organization Involved with Phase 2 Indications (36)
Organization Involved with Phase 1 Indications (12)
Organization Involved with Other Experimental Indications (21)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
